CLINICAL TRIAL: P3 RAN DB -LETROZOLE VS PLAC PRIMARY BR CA COMPLETING 5 OR 5+ YR

临床试验：P3 RAN DB -来曲唑 VS PLAC 主要 BR CA 完成 5 或 5 年

• 批准号: 7951360
• 负责人: CHRISTOPHER EHMANN
• 金额: $ 0.79万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951360
• 关键词: Affect; Aftercare; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Letrozole; Malignant Neoplasms; Quality of life; Research; Research Personnel; Resources; Running; Source; Tamoxifen; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Preliminary research suggests cancer recurring may be reduced if letrozole is taken after five years of tamoxifen. The purpose of this study is to find out whether it is better to receive letrozole or no further treatment after stopping tamoxifen. The second purpose is to determine how the treatment affects the quality of life.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 初步研究表明，如果在服用他莫昔芬五年后服用来曲唑，癌症复发可能会减少。 本研究的目的是找出是否接受来曲唑或停止他莫昔芬后，没有进一步的治疗更好。第二个目的是确定治疗如何影响生活质量。